Halozyme Therapeutics, Inc. (HALO) Stock Overview
NASDAQ · Healthcare · Biotechnology
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme…
Source: Yahoo Finance
Sector & Industry
Halozyme Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry group. It is listed on the NASDAQ exchange.
Halozyme Therapeutics, Inc. at a Glance
| Company | Halozyme Therapeutics, Inc. |
| Ticker | HALO |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $110.19 |
| Market cap | $12.51B |
| P/E ratio (trailing) | 32.31 |
| EPS (trailing) | $3.41 |
| 52-week high | $111.15 |
| 52-week low | $61.23 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | 0.88 |
| Return on equity (ROE) | 173.67% |
| Debt-to-equity | 1517.69% |
| Average volume | 1.96M |
| Shares outstanding | 113.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 423 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Frequently Asked Questions
- What is Halozyme Therapeutics, Inc.'s current P/E ratio?
- Halozyme Therapeutics, Inc. (HALO) has a trailing P/E ratio of 32.31 as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Halozyme Therapeutics, Inc.'s market capitalisation?
- Halozyme Therapeutics, Inc.'s market cap is $12.51B based on our latest snapshot. See how it ranks by market cap →
- What is HALO's 52-week range?
- Over the past 52 weeks, HALO has traded between $61.23 and $111.15. What does the 52-week range mean? →
- How volatile is Halozyme Therapeutics, Inc. compared to the market?
- Halozyme Therapeutics, Inc. has a beta of 0.88, meaning it has historically moved less than the broader market. What does beta measure? →
- Does Halozyme Therapeutics, Inc. pay a dividend?
- Halozyme Therapeutics, Inc. does not currently pay a dividend according to our latest data.
- What exchange is HALO listed on?
- HALO is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Halozyme Therapeutics, Inc. in?
- Halozyme Therapeutics, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
Working out potential returns or position sizes? Our payout and odds calculators handle the maths.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Philip Fisher on what makes a business worth owning for the long term.
Check Price →